Delving into the Latest Updates on HIV vaccine(Haikou Vti Biological Institute) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

HIV vaccine

+ [1]

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication

HIV Infections

Inactive Indication

Acquired Immunodeficiency Syndrome

Originator Organization

Haikou VTI Biological Institute

Active Organization

Haikou VTI Biological Institute

Inactive Organization

Guangdong South China New Drug Creation Center

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

[Translation] Exploring the efficacy and safety of the therapeutic (recombinant core antigen) AIDS vaccine B.C (LFnp24B.C) in combination with ART for the treatment of HIV-1 infected patients Multi-center Phase II clinical trial: LFnp24B.C Exploratory study of "functional cure" for HIV-1 infected patients in China

主要研究目的：评价 LFnp24B.C 联合 ART 治疗在抗病毒治疗中断（ATI）后对 HIV-1 感染者病毒载量的影响。次要研究目的： 1）评价 LFnp24B.C 联合 ART 治疗在 HIV-1 感染者中的安全性和免疫原性； 2）评价 LFnp24B.C 联合 ART 治疗对 HIV-1 感染者病毒储存库的影响。

[Translation]

Primary study objectives: To evaluate the effect of LFnp24B.C combined with ART treatment on the viral load of HIV-1 infected individuals after antiviral treatment interruption (ATI). Secondary study objectives: 1) To evaluate the safety and immunogenicity of LFnp24B.C combined with ART treatment in HIV-1 infected individuals; 2) To evaluate the effect of LFnp24B.C combined with ART treatment on the viral reservoir of HIV-1 infected individuals.

Start Date-

Sponsor / Collaborator

Haikou VTI Biological Institute

CTR20130371

/ CompletedPhase 1

随机、双盲、安慰剂对照评价治疗用（重组核心抗原）艾滋病疫苗B.C安全性和免疫原性I期临床试验

[Translation] A randomized, double-blind, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of the therapeutic (recombinant core antigen) AIDS vaccine B.C.

1.主要研究目的：评价LFn-p24B.C在ART治疗稳定的HIV-1 感染的HIV/AIDS患者中的安全性和耐受性 2.次要研究目的：评价LFn-p24B.C在ART治疗稳定的HIV-1 感染的HIV/AIDS患者中诱导特异性T细胞应答的能力

[Translation]

1. Primary study objective: To evaluate the safety and tolerability of LFn-p24B.C in HIV/AIDS patients with stable HIV-1 infection on ART 2. Secondary study objective: To evaluate the ability of LFn-p24B.C to induce specific T cell responses in HIV/AIDS patients with stable HIV-1 infection on ART

Start Date21 Apr 2014

Sponsor / Collaborator

Guangdong South China New Drug Creation Center

[+1]

ChiCTR-TRC-14004485

/ CompletedPhase 1IIT

A Randomized, Double-blind, Placebo-Controlled Trial To Evaluate The Safety And Immunogenicity Of LFnp24B.C, a Therapeutic HIV Vaccine,in HIV-infected Chinese Patients Receiving Stable ART treatment

Start Date10 Apr 2014

Sponsor / Collaborator-

100 Clinical Results associated with HIV vaccine(Haikou Vti Biological Institute)

Login to view more data

100 Translational Medicine associated with HIV vaccine(Haikou Vti Biological Institute)

Login to view more data

100 Patents (Medical) associated with HIV vaccine(Haikou Vti Biological Institute)

Login to view more data

100 Deals associated with HIV vaccine(Haikou Vti Biological Institute)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 2	China	Haikou VTI Biological Institute	12 Jan 2021
Acquired Immunodeficiency Syndrome	Phase 2	China	Guangdong South China New Drug Creation Center	21 Apr 2014
Acquired Immunodeficiency Syndrome	Phase 2	China	Haikou VTI Biological Institute	21 Apr 2014